中国肿瘤外科杂志2024，Vol.16Issue(2)：143-147,5.DOI:10.3969/j.issn.1674-4136.2024.02.008
奥希替尼联合培美曲塞/铂类对表皮生长因子受体合并TP53基因突变的非小细胞肺癌疗效及预后分析
Efficacy and prognosis of osimertinib plus pemetrexed/platinum in non small cell lung cancer with EGFR and TP53 mutations
摘要
Abstract
Objective To explore the efficacy and prognostic analysis of osimertinib combined with pemetrexed/platinum in non-small cell lung cancer(NSCLC)with EGFR and TP53 mutations.Methods Eighty patients with NSCLC with EGFR and TP53 mutations,who were diagnosed in 904th Hospital of Joint Logistics Support Force between January 2016 and June 2022,were randomly selected for this study.They were randomly divided into a control(40 patients)group and a study(40 patients)group.The control group received Osimertinib treatment,while the study group received pemetrexed/platinum combined with osimertinib treatment.The clinical efficacy,serum indicator levels,medication safety,and prognosis of the two groups were compared.Results The overall response rate(ORR)and disease control rate(DCR)of the study group were significantly better than those of the control group(P＜0.05).After treatment,the levels of cytokeratin 19 fragment(CYFRA21-1),and carcinoembryonic antigen(CEA)were significantly lower in both groups than before treatment(P＜0.05),and they were significantly lower in the study group than in the control group(P＜0.05).After treatment,the levels of interleukin 4(IL-4),vascular endothelial growth factor(VEGF),and intercellular adhesion molecule-1(ICAM-1)were significantly lower in both groups than before treatment(P＜0.05),and they were significantly lower in the study group than in the control group(P＜0.05).There was no statistically significant difference in adverse effects between the two groups(P＞0.05).The survival rate of the study group after 1 year of follow-up was significantly higher than that of the control group(P＜0.05).After treatment,the EORTC QLQ-C30 score of the two groups was higher than before treatment(P＜0.05),and the score of the study group was higher than that of the control group(P＜0.05).Conclusions Osimertinib combined with pemetrexed/platinum based chemotherapy regimen is used in the clinical treatment of NSCLC with EGFR and TP53 mutations,which can effectively exert antitumor effects,downgrade the level of inflammation,enhance the efficacy,and improve patient prognosis.And the medication has a high safety and does not significantly increase adverse reactions.关键词
非小细胞肺癌/EGFR合并TP53基因突变/培美曲塞/顺铂/奥希替尼/疗效/预后Key words
Non-small cell lung cancer/EGFR combined with TP53 gene mutation/Pemetrexed/Cisplatin/Osimertinib/Efficacy/Prognosis引用本文复制引用
王伟,周伟..奥希替尼联合培美曲塞/铂类对表皮生长因子受体合并TP53基因突变的非小细胞肺癌疗效及预后分析[J].中国肿瘤外科杂志,2024,16(2):143-147,5.基金项目
江苏省研究生科研与实践创新计划项目(SJCX21＿1152) （SJCX21＿1152）
